Isosceles Pharmaceuticals is a preclinical stage biotech company that is working on perioperative acute pain product candidates.
Isosceles Pharmaceuticals has raised $5.0M in total funding. The most recent round was Equity Crowdfunding. The last funding was announced in October 2022.
Isosceles Pharmaceuticals's investors include Equifund.
Isosceles Pharmaceuticals is headquartered in Wilmington, United States.
Isosceles Pharmaceuticals is a preclinical stage biotech company that is working on perioperative acute pain product candidates.
Isosceles Pharmaceuticals is at the Equity Crowdfunding stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Isosceles Pharmaceuticals — Funding & Investors." VCBacked, October 3, 2022, https://www.vcbacked.co/company/isosceles-pharmaceuticals. Accessed November 13, 2026.
VCBacked. (2022). Isosceles Pharmaceuticals — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/isosceles-pharmaceuticals
{{cite web |title=Isosceles Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/isosceles-pharmaceuticals |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Isosceles Pharmaceuticals? Request a listing update